On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for metastatic colorectal cancer by three months.
• Exelixis stock is under selling pressure. Why is EXEL stock retreating?
In response to an FDA information request, Exelixis submitted updated safety and efficacy data, which the FDA has deemed a major amendment.
The updated Prescription Drug User Fee Act action date is March 3, 2027.
Analyst View
